Amgen Stock News

Amgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance.

The pharmaceutical company's second-quarter numbers were roughly in line with expectations. Amgen's slight earnings miss, however, was enough to spark a sizeable sell-off.

Amgen NASDAQ: AMGN is a biotechnology firm that has made its way into the weight loss treatment battle. The company's shares have performed relatively well in 2024, providing a total return of 16%, outpacing its sector and the market.

Amgen Inc. (NASDAQ:AMGN ) Q2 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Bob Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) Jay Bradner - EVP, Research and Development & Chief Sc...

Amgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat.

Amgen on Tuesday said its second-quarter profit slipped 1% as higher expenses offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.

THOUSAND OAKS, Calif. , Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024.

Dow Jones biotech giant Amgen, along with MercadoLibre, Ferrari and Lennar, are in or near buy zones in today's stock market sell-off.